Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 6/20 | 0.53 |
| ▸ | JAK3 | P52333 | 5/20 | 0.53 |
| ▸ | JAK2 | O60674 | 4/20 | 0.53 |
| ▸ | TYK2 | P29597 | 3/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | AKT2 | P31751 | 2/20 | 0.52 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | IDE | P14735 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23041357 | 0.94 | AKT1 (0.50) | JAK1JAK3JAK2TYK2AKT1 | |
| SCHEMBL12612978 | 0.86 | JAK1 (0.50) | JAK1JAK3JAK2TYK2KIT | |
| SCHEMBL3721916 | 0.83 | PIK3CD (0.56) | AKT1AKT2KITACHENUDT1 | |
| SCHEMBL22553696 | 0.83 | PBK (0.50) | JAK1JAK3JAK2TYK2AKT1 | |
| SCHEMBL30945074 | 0.82 | KIT (0.64) | JAK1JAK3AKT1KIT | |
| SCHEMBL28367516 | 0.82 | KIT (0.64) | JAK1JAK3AKT1KIT | |
| SCHEMBL3342258 | 0.82 | POLB (0.52) | JAK1KITACHE | |
| SCHEMBL28092265 | 0.82 | AKT2 (0.51) | JAK3AKT1AKT2PBKNUDT1 | |
| SCHEMBL16026477 | 0.82 | AKT2 (0.59) | AKT1AKT2PBKKITNUDT1 | |
| SCHEMBL5760446 | 0.82 | AKT1 (0.52) | AKT1KITACHEIDEDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| CN-111566102-B | Substituted pyrrolopyridines as activin receptor-like kinase inhibitors | 缆图药品公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-3697786-B1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORP (US) | 2022-08-31 | — | — | EP | disclosed |
| US-11236086-B2 | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200331908-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2020-10-22 | — | — | US | disclosed |
| EP-3697786-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | Blueprint Medicines Corporation (US) | 2020-08-26 | — | — | EP | disclosed |
| CN-111566102-A | Substituted pyrrolopyridines as activin receptor-like kinase inhibitors | 缆图药品公司 | 2020-08-21 | — | — | CN | disclosed |
| WO-2019079649-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2019-04-25 | — | — | WO | disclosed |
| US-9650379-B2 | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-16 | — | — | US | disclosed |
| US-9650379-B2 | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-16 | — | — | US | disclosed |
| EP-1858869-A1 | ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| EP-1856077-A1 | PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094840-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094843-A1 | PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094843-A1 | PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094840-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| US-20050090496-A1 | Sulphonyl compounds with 5-ht6 receptor affinity | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090496-A1 | Sulphonyl compounds with 5-ht6 receptor affinity | HTR6, HTR4, HTR5A | JAK1 3502/4885JAK3 2244/4885JAK2 1756/4885 |
| US-11236086-B2 | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase | ALK, ACVR1, ACVR2A | JAK1 1231/4885JAK3 1073/4885JAK2 712/4885 |
| US-20200331908-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ALK, ACVR1, ACVR2A | JAK1 1231/4885JAK3 1073/4885JAK2 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.